- Email: [email protected]
Secukinumab in real practice treatment of moderate to severe psoriasis - a 9 patient case report
4432
4744
Secukinumab in psoriasis patients with concurrent psoriatic arthritis: Patient-reported outcomes in the Corrona Psoriasis Registry Alice B. Gottlieb, New York Medical College; Bruce Strober, University of Connecticut Health Center; April W. Armstrong, University of Southern California; Jeffrey D. Greenberg, Corrona LLC; Chitra Karki, Corrona LLC; Marc Mason, Corrona LLC; Isabelle Gilloteau, Novartis Pharma AG; Adriana Guana, Novartis Pharmaceuticals Corporation; Mark Lebwohl, Icahn School of Medicine at Mount Sinai Background: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile. The Corrona Psoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US. Psoriasis can have significant burden on quality of life. This presentation describes patient reported outcomes (PROs) in psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment. Methods: Adult patients who started/switched to a systemic therapy at enrollment or in the previous 12 months, and with a concurrent PsA diagnosis based on clinical judgement of the treating dermatologist were included in this study. Patients were stratified by drug groups: biologics (secukinumab, etanercept [ETN], adalimumab [ADA], ustekinumab [UST]) and nonbiologics [NB]. PRO data at enrollment were collected through questionnaires: work productivity and activity impairment [WPAI; effects of psoriasis on ability to work and perform regular activities, scale 0 100], health status [EQ-5D-3L, visual analog scale (VAS) 0 100; 0 ¼ worst, 100 ¼ best], and dermatology-related quality of life [DLQI; VAS 0 30; 0 ¼ no effect on life]. Fatigue, pain and itch were measured on a VAS scale of 0 100 (0 ¼ none; 100 ¼ very severe).
Secukinumab patient demographics and disease characteristics in the Corrona Psoriasis Registry Bruce Strober, MD, University of Connecticut; April W. Armstrong, MD, University of Southern California; Jeff D. Greenberg, MD, Corrona LLC; Chitra Karki, MPH, Corrona, LLC; Marc Mason, Corrona, LLC; Ning Guo, Corrona, LLC; Isabelle Gilloteau, Novartis Pharma AG; Adriana Guana, Novartis Pharmaceuticals; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai
Results: As of May 31 2016, 1529 psoriasis patients were enrolled in registry; 619 (40.5%) had a PsA diagnosis (mean disease duration 7.9 years) of which 35% were biologic na€ıve. Of the 619 patients with PsA, 25.0% received secukinumab, 5.7% ETN, 18.7% ADA, 16.8% UST, and 32.3% NB. Pain scores were higher in the secukinumab group: mean 25.8 overall, 33.3 secukinumab, 21.7 ETN, 24.9 ADA, 20.0 UST, 24.4 NB. Fatigue and itch mean scores were similar across the treatments. Overall 60% were currently employed, with a lower proportion in the secukinumab group (56%) compared with 66% ETN, 59% ADA, 59% UST, 51% NB. However, patients in the different treatment groups had similar work absenteeism, impairment at work, and impairment in daily activities due to psoriasis. Patients at enrollment had a moderate effect of psoriasis on their quality of life (overall mean ¼ 6.8 and 69.0 for DLQI and EQ-5D-3L, respectively) but no difference was observed across the treatment groups.
Introduction and Objectives: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, was approved for moderate to severe plaque psoriasis (PsO) in 2015. The Corrona PsO registry was launched in April 2015 to study the comparative safety of approved systemic PsO therapies in a real world setting. This abstract describes the characteristics at enrollment of patients treated with secukinumab compared to those receiving other systemic treatments. Material and Methods: The Corrona PsO registry is a large independent diseasebased registry targeting to enroll about 10,000 PsO patients $18 years from ;200 US sites, who initiated or switched to a systemic therapy (biologic or non-biologic) at enrollment (incident user) or in the previous 12 months (prevalent user). All PsO patients enrolled between 15th Apr 2015 and 31st Jan 2016 were included. Descriptive analyses on patient characteristics were evaluated at enrollment. Results: In comparison to the overall PsO patients enrolled by 31st Jan 2016 (n ¼ 1014), the 236 patients treated with secukinumab had similar mean age (51.2 years secukinumab vs 50.6 years overall), fewer females (39% vs 45%), higher mean BMI (32.0 vs 30.5 kg/m2), mean body weight (95.1 vs 89.4 kg), mean disease duration (20.0 vs 15.7 years) and smoking history (56% vs 52%), but were less biologic na€ıve (9% vs 43%). In comparison to the other biologic treated patients, patients treated with secukinumab had higher prevalence of hypertension (41% vs 34%), diabetes (19% vs 14%), psoriatic arthritis (46% vs 44%), cardiovascular disease (14% vs 11%) and hyperlipidemia (28% vs 25%), respectively. Similarly, body surface area (BSA; 9.9% vs 7.7%), the Investigator’s Global Assessment mod 2011 score (IGA; 2.3 vs 2.1) and the Psoriasis Activity Severity Index 0-72 score (PASI; 6.1 vs 5.0) for the secukinumab cohort were slightly higher in comparison to the other biologic cohort, respectively. Conclusions: Descriptive analysis at registry enrollment show that the majority of secukinumab patients are not biologic na€ıve compared to those on other systemic therapies. Secukinumab patients also have higher body weight, disease duration, BSA and comorbidities compared to those on other biologic therapies. Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen.
Conclusions: Patient-reported quality of life at enrollment in the Corrona psoriasis registry was comparable across all treatment groups. Secukinumab treated PsA patients reported having greater pain at enrollment. This descriptive overview of the PROs is crucial before investigating prospective and comparative analyses between treatment groups as data mature in this registry. Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen.
4760 Secukinumab in real practice treatment of moderate to severe psoriasis - a 9 patient case report Guillermo Ramirez Fernandez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Jose Suarez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Noelia Hernandez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Ricardo Fernandez de Misa, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria; Javier Merino, MD, Pharmacy Unit, University Hospital Nuestra Se~ nora de Candelaria Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has recently been approved for the first-line therapy of psoriasis. We present 9 psoriasis patients (5 male and 4 female; age range 31-67) diagnosed of different types of moderate-tosevere psoriasis (5 plaque psoriasis, 1 psoriasis pustulosa, 1 plaque and palmoplantar psoriasis, 1 psoriatic arthritis with palmoplantar psoriasis and 1 erythrodermic psoriasis) treated with secukinumab for their disease. Six of nine patients where not naive for biological therapies and they had previously been treated with diverse classic or systemic treatments for their psoriasis (used alone or in combinations that included: topical therapy, phototherapy, methotrexate, acitretin, cyclosporine, ustekinumab, adalimumab or etanercept) that were discontinued due to side effects or lack of response. Three patients were na€ıve for biologics. All patients were treated with the recommended secukinumab dosage schedule, being induced between February and September 2016; some continued receiving topical or systemic classic therapies. A control of psoriatic skin disease was achieved in most patients without side effects, although a patient referred transient reddening of the skin and itching after the first doses of secukinumab. We report clinical findings, PASI response, used switching strategies, associated used therapies and comorbidities of a small but varied series of 9 patients with difficult-to-manage psoriasis treated with secukinumab in real practice of a tertiary hospital. Commercial support: None identified.
AB228
J AM ACAD DERMATOL
JUNE 2017
4744
Secukinumab in psoriasis patients with concurrent psoriatic arthritis: Patient-reported outcomes in the Corrona Psoriasis Registry Alice B. Gottlieb, New York Medical College; Bruce Strober, University of Connecticut Health Center; April W. Armstrong, University of Southern California; Jeffrey D. Greenberg, Corrona LLC; Chitra Karki, Corrona LLC; Marc Mason, Corrona LLC; Isabelle Gilloteau, Novartis Pharma AG; Adriana Guana, Novartis Pharmaceuticals Corporation; Mark Lebwohl, Icahn School of Medicine at Mount Sinai Background: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has significant efficacy in the treatment of moderate to severe psoriasis and psoriatic arthritis (PsA) with a favorable safety profile. The Corrona Psoriasis Registry is an independent observational cohort to compare the safety of FDA-approved systemic treatments in moderate to severe psoriasis in the US. Psoriasis can have significant burden on quality of life. This presentation describes patient reported outcomes (PROs) in psoriasis patients with concurrent PsA treated with secukinumab and other systemic treatments at registry enrollment. Methods: Adult patients who started/switched to a systemic therapy at enrollment or in the previous 12 months, and with a concurrent PsA diagnosis based on clinical judgement of the treating dermatologist were included in this study. Patients were stratified by drug groups: biologics (secukinumab, etanercept [ETN], adalimumab [ADA], ustekinumab [UST]) and nonbiologics [NB]. PRO data at enrollment were collected through questionnaires: work productivity and activity impairment [WPAI; effects of psoriasis on ability to work and perform regular activities, scale 0 100], health status [EQ-5D-3L, visual analog scale (VAS) 0 100; 0 ¼ worst, 100 ¼ best], and dermatology-related quality of life [DLQI; VAS 0 30; 0 ¼ no effect on life]. Fatigue, pain and itch were measured on a VAS scale of 0 100 (0 ¼ none; 100 ¼ very severe).
Secukinumab patient demographics and disease characteristics in the Corrona Psoriasis Registry Bruce Strober, MD, University of Connecticut; April W. Armstrong, MD, University of Southern California; Jeff D. Greenberg, MD, Corrona LLC; Chitra Karki, MPH, Corrona, LLC; Marc Mason, Corrona, LLC; Ning Guo, Corrona, LLC; Isabelle Gilloteau, Novartis Pharma AG; Adriana Guana, Novartis Pharmaceuticals; Mark Lebwohl, MD, Icahn School of Medicine at Mount Sinai
Results: As of May 31 2016, 1529 psoriasis patients were enrolled in registry; 619 (40.5%) had a PsA diagnosis (mean disease duration 7.9 years) of which 35% were biologic na€ıve. Of the 619 patients with PsA, 25.0% received secukinumab, 5.7% ETN, 18.7% ADA, 16.8% UST, and 32.3% NB. Pain scores were higher in the secukinumab group: mean 25.8 overall, 33.3 secukinumab, 21.7 ETN, 24.9 ADA, 20.0 UST, 24.4 NB. Fatigue and itch mean scores were similar across the treatments. Overall 60% were currently employed, with a lower proportion in the secukinumab group (56%) compared with 66% ETN, 59% ADA, 59% UST, 51% NB. However, patients in the different treatment groups had similar work absenteeism, impairment at work, and impairment in daily activities due to psoriasis. Patients at enrollment had a moderate effect of psoriasis on their quality of life (overall mean ¼ 6.8 and 69.0 for DLQI and EQ-5D-3L, respectively) but no difference was observed across the treatment groups.
Introduction and Objectives: Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, was approved for moderate to severe plaque psoriasis (PsO) in 2015. The Corrona PsO registry was launched in April 2015 to study the comparative safety of approved systemic PsO therapies in a real world setting. This abstract describes the characteristics at enrollment of patients treated with secukinumab compared to those receiving other systemic treatments. Material and Methods: The Corrona PsO registry is a large independent diseasebased registry targeting to enroll about 10,000 PsO patients $18 years from ;200 US sites, who initiated or switched to a systemic therapy (biologic or non-biologic) at enrollment (incident user) or in the previous 12 months (prevalent user). All PsO patients enrolled between 15th Apr 2015 and 31st Jan 2016 were included. Descriptive analyses on patient characteristics were evaluated at enrollment. Results: In comparison to the overall PsO patients enrolled by 31st Jan 2016 (n ¼ 1014), the 236 patients treated with secukinumab had similar mean age (51.2 years secukinumab vs 50.6 years overall), fewer females (39% vs 45%), higher mean BMI (32.0 vs 30.5 kg/m2), mean body weight (95.1 vs 89.4 kg), mean disease duration (20.0 vs 15.7 years) and smoking history (56% vs 52%), but were less biologic na€ıve (9% vs 43%). In comparison to the other biologic treated patients, patients treated with secukinumab had higher prevalence of hypertension (41% vs 34%), diabetes (19% vs 14%), psoriatic arthritis (46% vs 44%), cardiovascular disease (14% vs 11%) and hyperlipidemia (28% vs 25%), respectively. Similarly, body surface area (BSA; 9.9% vs 7.7%), the Investigator’s Global Assessment mod 2011 score (IGA; 2.3 vs 2.1) and the Psoriasis Activity Severity Index 0-72 score (PASI; 6.1 vs 5.0) for the secukinumab cohort were slightly higher in comparison to the other biologic cohort, respectively. Conclusions: Descriptive analysis at registry enrollment show that the majority of secukinumab patients are not biologic na€ıve compared to those on other systemic therapies. Secukinumab patients also have higher body weight, disease duration, BSA and comorbidities compared to those on other biologic therapies. Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen.
Conclusions: Patient-reported quality of life at enrollment in the Corrona psoriasis registry was comparable across all treatment groups. Secukinumab treated PsA patients reported having greater pain at enrollment. This descriptive overview of the PROs is crucial before investigating prospective and comparative analyses between treatment groups as data mature in this registry. Commercial support: This study is sponsored by Corrona, LLC. The Corrona Psoriasis Registry is funded by Novartis Pharmaceutical Corporation and Eli Lilly and Company. Corrona, LLC. has been supported through contracted subscriptions in the last two years by AbbVie and Amgen.
4760 Secukinumab in real practice treatment of moderate to severe psoriasis - a 9 patient case report Guillermo Ramirez Fernandez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Jose Suarez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Noelia Hernandez, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria.; Ricardo Fernandez de Misa, MD, Dermatology Unit, University Hospital Nuestra Se~ nora de Candelaria; Javier Merino, MD, Pharmacy Unit, University Hospital Nuestra Se~ nora de Candelaria Secukinumab, a fully human anti-interleukin-17A monoclonal antibody, has recently been approved for the first-line therapy of psoriasis. We present 9 psoriasis patients (5 male and 4 female; age range 31-67) diagnosed of different types of moderate-tosevere psoriasis (5 plaque psoriasis, 1 psoriasis pustulosa, 1 plaque and palmoplantar psoriasis, 1 psoriatic arthritis with palmoplantar psoriasis and 1 erythrodermic psoriasis) treated with secukinumab for their disease. Six of nine patients where not naive for biological therapies and they had previously been treated with diverse classic or systemic treatments for their psoriasis (used alone or in combinations that included: topical therapy, phototherapy, methotrexate, acitretin, cyclosporine, ustekinumab, adalimumab or etanercept) that were discontinued due to side effects or lack of response. Three patients were na€ıve for biologics. All patients were treated with the recommended secukinumab dosage schedule, being induced between February and September 2016; some continued receiving topical or systemic classic therapies. A control of psoriatic skin disease was achieved in most patients without side effects, although a patient referred transient reddening of the skin and itching after the first doses of secukinumab. We report clinical findings, PASI response, used switching strategies, associated used therapies and comorbidities of a small but varied series of 9 patients with difficult-to-manage psoriasis treated with secukinumab in real practice of a tertiary hospital. Commercial support: None identified.
AB228
J AM ACAD DERMATOL
JUNE 2017